EvaLAMP: LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Study Details
Study Description
Brief Summary
This study will evaluate the of the loop-mediated amplification assay (LAMP) as a diagnostic as well as a Test-of-Cure (ToC) for visceral leishmaniasis (VL) in an endemic area in Ethiopia. Furthermore, we aim to further development of the direct-blood PCR-Nucleic Acid Lateral-Flow Immuno-Assay (dB-PCR-NALFIA) as a novel diagnostic tool for VL and its subsequent evaluation in the field.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Leishmaniasis is among the World's important neglected infectious diseases (NIDs). The WHO estimates that 350 million people are at risk of contracting leishmaniasis. Visceral leishmaniasis (VL) is the most severe form of the disease. Ethiopia has been recently listed by WHO among the fourteen countries in the world with the highest burden of VL. The development of novel point-of-care (PoC) diagnostics and/or a Test-of-Cure (ToC) for VL is deemed a key priority research area. In several endemic areas current gold standard diagnosis and monitoring of treatment efficacy of VL is based on parasite detection or serology. However, these tests are either not available for routine use or lack sufficient sensitivity and specificity, in particular in HIV co-infected patients. Though molecular tests such as PCR have become popular choices as a tool to diagnose VL, monitor treatment response and predict relapse, these techniques require technical skill and equipment and are considerably more expensive. Recent advances in diagnostics has been the development of LAMP with several advantages, such as no need for thermocycler, high specificity, simple read-out and no cold chain requirements. Therefore, LAMP has emerged as a powerful tool for PoC diagnostics. Its clinical utility as PoC diagnosis and/or ToC for VL in the African setting is, however, hardly known.
Here, the investigators will evaluate the utility of the LAMP as a PoC and/or ToC for VL in an endemic area in Ethiopia. The performance of the LAMP assay as a diagnostic tool will be evaluated in newly diagnosed VL cases confirmed by parasite detection and/or PCR. Furthermore, the use of the assay as ToC will be determined by evaluating the performance of the assay in VL patients confirmed cured at day 17 of therapy, as assessed by negative parasite and/or PCR results. Additionally, the investigators plan to utilize a newly developed rapid molecular platform, db-PCR-NALFIA, which does not require DNA extraction, has an internal amplification control and simple read-out. The investigators will evaluate the utility of both assays also in patients co-infected with HIV. The results may have major policy implications as the application represents a concept that could enhance evidence- based translation of research to improve public health practice by contributing to leishmaniasis management guidelines - with overarching impacts for National, Regional and Global programs.
Study Design
Outcome Measures
Primary Outcome Measures
- Number of participants correctly diagnosed with VL as assessed by LAMP assay [Baseline]
Performance of the LAMP will be compared to gold- standard diagnostic procedures, including parasite detection and/or PCR-technology
- Number of participants treated for VL and identified as cured (ToC) at day 17 post-treatment based on the assessment by LAMP assay [Baseline]
LAMP will be compared to gold- standard diagnostic procedures, including parasite detection and/or PCR-technology
Secondary Outcome Measures
- Number of participants co-infected with HIV correctly diagnosed with VL as well as treated participants identified as cured (ToC) at day 17 based on the assessment by LAMP assay [17 days]
LAMP will be compared to gold-standard diagnostic procedures, including parasite detection and/or PCR-technology
- Number of participants correctly diagnosed as VL based on db-PCR-NALFIA technology [Baseline]
The investigators will develop db-PCR-NALFIA technology for the diagnosis of VL, i.e. sample preparation and result read-out will be adopted using db-PCR-NALFIA technology as PoC platform. It's performance will be evaluated against gold-standard.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Clinical evidence consistent with VL confirmed by microscopy (+ culture) and/or PCR
Exclusion Criteria:
-
Treatment with any anti-leishmanial drugs within the previous 3 months
-
Not capable of understanding or complying with the study protocol
-
Refusal to consent and participate in to the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mekelle University College of Health Sciences | Mekele | Ethiopia |
Sponsors and Collaborators
- Prof. Dawit Wolday
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
- Study Chair: Amanuel Haile, MD, Mekelle University College of Health Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TMA2016SF-1437